You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

Details for Patent: 10,717,721


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 10,717,721 protect, and when does it expire?

Patent 10,717,721 protects AKYNZEO and is included in one NDA.

This patent has sixty-seven patent family members in forty-nine countries.

Summary for Patent: 10,717,721
Title:Substituted piperaziniums for the treatment of emesis
Abstract: Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the neurokinin (NK.sub.1) receptor. The compounds have the general formula (I): ##STR00001##
Inventor(s): Fadini; Luca (Giubiasco, CH), Manini; Peter (Giubiasco, CH), Pietra; Claudio (Como, IT), Giuliano; Claudio (Como, IT), Lovati; Emanuela (Mendrisio, CH), Cannella; Roberta (Varese, IT), Venturini; Alessio (Varese, IT), Stella; Valentino J. (Lawrence, KS)
Assignee: Helsinn Healthcare SA (Lugano/Pazzallo, CH)
Application Number:16/228,835
Patent Claim Types:
see list of patent claims
Compound;

Drugs Protected by US Patent 10,717,721

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Helsinn Hlthcare AKYNZEO fosnetupitant chloride hydrochloride; palonosetron hydrochloride POWDER;INTRAVENOUS 210493-001 Apr 19, 2018 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Helsinn Hlthcare AKYNZEO fosnetupitant chloride hydrochloride; palonosetron hydrochloride SOLUTION;INTRAVENOUS 210493-002 May 27, 2020 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 10,717,721

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 2785706 ⤷  Sign Up 301047 Netherlands ⤷  Sign Up
European Patent Office 2785706 ⤷  Sign Up CA 2020 00028 Denmark ⤷  Sign Up
European Patent Office 2785706 ⤷  Sign Up PA2020510 Lithuania ⤷  Sign Up
European Patent Office 2785706 ⤷  Sign Up LUC00158 Luxembourg ⤷  Sign Up
European Patent Office 2785706 ⤷  Sign Up 2020C/516 Belgium ⤷  Sign Up
European Patent Office 2785706 ⤷  Sign Up 122020000046 Germany ⤷  Sign Up
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.